The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
News|Articles|April 21, 2005
Drug Recalls
Author(s)Pharmaceutical Technology Editors
Drug Recall
Advertisement
The US Food and Drug Administration has logged three
- On March 15, McKesson Packaging Services (Concord, NC), startedsending out letters recalling 4755 boxes of institutional-useSky brand blister packs and punch cards of acetaminophen (manufacturedby Magno-Humphries Laboratories of Tigard, OR) that might contain metalparticles.
- On March 11, Malinckrodt (Berkeley, MO) began its recall of1194 thousand-tablet bottles of propoxyphene napsylate andacetaminophen tablets because the bottle label referred to pinktablets, while those batches of the product were white.
- On April 4, Wyeth's Richmond Division (Richmond, VA) becanrecalling 28,727 thousand-tablet bottles of Premarin conjugatedestrogen tablets (in 0.625 and 0.3 mg dosages), citing dissolution failures.
–Douglas McCormick
Advertisement
Related to this article
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
Ask the Expert: Post-Approval Changes
5